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Diego, San Diego, United States; 2Department of Cellular and Molecular Medicine,
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Abstract Endothelial cells (ECs) are critical determinants of vascular homeostasis and
inflammation, but transcriptional mechanisms specifying their identities and functional states
remain poorly understood. Here, we report a genome-wide assessment of regulatory landscapes of
primary human aortic endothelial cells (HAECs) under basal and activated conditions, enabling
inference of transcription factor networks that direct homeostatic and pro-inflammatory programs.
We demonstrate that 43% of detected enhancers are EC-specific and contain SNPs associated to
cardiovascular disease and hypertension. We provide evidence that AP1, ETS, and GATA
transcription factors play key roles in HAEC transcription by co-binding enhancers associated with
EC-specific genes. We further demonstrate that exposure of HAECs to oxidized phospholipids or
pro-inflammatory cytokines results in signal-specific alterations in enhancer landscapes and
associate with coordinated binding of CEBPD, IRF1, and NFkB. Collectively, these findings identify
cis-regulatory elements and corresponding trans-acting factors that contribute to EC identity and
their specific responses to pro-inflammatory stimuli.
DOI: 10.7554/eLife.22536.001
Introduction
Atherosclerosis is an inflammatory disease of large arteries mediated by the accumulation of plaque
within the vessel wall. Through sequelae such as heart attack, stroke, and peripheral vascular dis-
ease, it is responsible for an immense burden of morbidity and mortality. The pathogenesis of ath-
erosclerosis involves several cell types and environmental risk factors (Lusis, 2000; Glass and
Witztum, 2001). One of the critical cell types is the arterial endothelial cell (EC). The onset of ath-
erosclerosis involves the activation of ECs by pro-inflammatory micro-environmental exposures
including hemodynamic turbulence, oxidized-specific epitopes, and inflammatory
cytokines (Tabas et al., 2015). These inflammatory stimuli result in the expression of adhesion mole-
cules on the luminal EC surface and rolling, attachment, and migration of leukocytes into the vessel
wall. Sustained recruitment and accumulation of immune cells in the vessel wall leads to extracellular
matrix remodeling, smooth muscle cell migration, and the development of necrotic debris. Acute
plaque rupture can result in sudden vascular occlusion, leading to heart attack or stroke.
Genome-wide association studies have identified more than 50 loci that predispose humans to
cardiovascular disease (CVD) (Nikpay et al., 2015), of which the major cause is atherosclerosis. The
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majority of CVD loci reside outside protein-coding regions of the genome, suggesting that the risk
variants alter gene regulatory function (Hindorff et al., 2009; Manolio, 2010). Still, the target
genes, pathways, and cell types of action are largely unknown due to challenges in linking regulatory
variants to function. A major challenge is that mammalian genomes contain upwards of a million
potential regulatory elements called enhancers, yet a given cell type only utilizes on the order of
tens of thousands of active enhancers (ENCODE Project Consortium, 2012; Andersson et al.,
2014). This makes it difficult to accurately predict the functional cell systems and units of regulation
from sequence alone (Shlyueva et al., 2014).
An important insight into enhancer biology is the observation that unique combinations of a few
transcription factors (TFs) together activate cell-type-specific enhancers. Enhancer priming by TFs is
both collaborative, (such that one TF will not bind its DNA motif if the motif for a collaborating TF is
mutated [Heinz et al., 2013]), and hierarchical (the majority of sites bound by newly abundant TFs
occur at enhancers pre-bound by collaborating TFs [Heinz et al., 2015; Romanoski et al., 2015;
Kaikkonen et al., 2013]). This model is perhaps best characterized in the hematopoietic system and
with toll-like receptor 4 signaling (Heinz et al., 2013; Kaikkonen et al., 2013; Heinz et al., 2010).
For example, myeloid-specific enhancer activation and cell differentiation requires the TF PU.1 in
combination with C/EBPb, whereas B cells require PU.1 in combination with EBF and
E2A (Heinz et al., 2010).
In the current study, we take a genome-wide approach using DNA variation, epigenetic, and tran-
scriptomic data to identify the major TF families that coordinate human aortic endothelial cell
(HAEC) gene expression in homeostasis and upon exposure to prototypic inflammatory stimuli char-
acteristic of atherosclerosis. Using a combination of experimental and computational approaches,
we find that members of the ETS and AP1 TF families bind EC enhancers and that removing ETS
member ERG elicits an inflammatory profile. We demonstrate that many enhancers identified in ECs
are cell type-specific and several enhancers overlap with SNPs that have been associated to coronary
artery disease (CAD) and hypertension. In addition, we demonstrate that TFs NRF2, NFkB, CEBD,
and IRF1 are signal-dependent TFs that mediate the EC response to inflammatory stimuli.
Results
Transcription factors in the AP1 and ETS families dominate the
enhancer landscape in HAECs
A total of 16,929 high-confidence enhancer-like elements were mapped in HAECs (Figure 1a) using
chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) to identify pro-
moter-distal elements marked by significant levels of histone H3 di-methylation of lysine 4
(H3K4me2) and acetylation of lysine 27 (H3K27ac) that together mark active enhancers
(Heintzman et al., 2007; Creyghton et al., 2010; Rada-Iglesias et al., 2011). Chromatin accessibil-
ity, measured by Assay for Transposase Accessible Chromatin with high-throughput sequencing
(ATAC-seq [Buenrostro et al., 2013]), was used to center the enhancer-like regions. The position
within the element with the maximum signal that reflects greatest accessibility was used for center-
ing. Using public global nuclear run-on sequencing (GRO-seq) data in HAECs (Kaikkonen et al.,
2014), we observed that our set of enhancer-like loci produced bi-directional nascent RNA tran-
scripts, or enhancer RNAs (eRNAs), as evidenced by the red and blue strand-specific RNA signals in
Figure 1a. The potential function of eRNAs is not understood; however, eRNA output is robustly
correlated with enhancer activity (Kaikkonen et al., 2014; Lam et al., 2013; De Santa et al., 2010;
Kim et al., 2010), further supporting our enhancer set as active EC enhancers (Figure 1a).
We hypothesized that the major TFs that select and maintain enhancers in HAECs would be evi-
dent via enrichment of binding motifs in enhancer DNA sequences. Thus, we performed de novo
motif enrichment analysis and discovered that AP1, ETS, SOX and GATA motifs were significantly
enriched (-logPvalues > 7.1e2) in HAEC enhancers compared to random GC-matched genomic back-
ground sequence (Figure 1b, comprehensive list in Figure 1—figure supplement 1). Based on pre-
vious evidence (Heinz et al., 2013), we expected for functional motifs to be enriched near the
maximum signal for chromatin accessibility. Indeed, AP1 and ETS were most frequently observed
near the signal maximum, whereas the relationships for SOX and GATA motifs were less pronounced
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Figure 1. HAECs display a distinct repertoire of enhancers that nominate combinations of the AP1, ETS, SOX and GATA TF families as major
orchestrators of HAEC gene expression. (a) A heatmap of 16,929 enhancer-like regions were selected by: accessible chromatin (ATAC-seq), coincident
with H3K4me2 and H3K27ac deposition (ChIP-seq) in gene-distal positions (3 kb from promoters). Rows are enhancer loci, repeated for each data
type in columns. Bidirectional transcription of enhancer RNAs (eRNAs) is also evident (GRO-seq). (b) The top four enriched motifs that occur in
enhancers from a are shown. The transcription factor (TF) family, de novo motif matrix, percentage motif occurrence at enhancer loci versus random
loci, and enrichment -logPvalues are indicated. Enrichment was calculated from 200 bp sequence, centered on chromatin accessibility. (c) The positional
enrichment of the enriched motifs are shown relative to the center of the enhancer-like elements from a, where 0 bp is the center of the accessibility
signal. (d) Gene expression measured by RNA-seq and limited to TFs is ranked by FPKM values to nominate the most highly expressed TFs in the AP1,
ETS, SOX, and GATA families. (e, f) RNA expression, histone modifications, and super enhancer (SE) definitions are shown for: (e) ERG and (f) JUN loci.
SE regions are highlighted in yellow and were defined using H3K27ac. More related data in Figure 1—figure supplements 1–3.
Figure 1 continued on next page
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(Figure 1c). These data nominate roles for AP1 and ETS TF members as important mediators of the
HAEC enhancer landscape.
Tens of genes encode proteins of the AP1, ETS, SOX and GATA TF families. Within each family
different members share nearly identical DNA-binding domains and thus bind the same motif. In
addition, AP1 protein members bind AP1 motifs as homo- and hetero-dimers. These sources of
redundancy make it challenging to identify the functional family member(s) without additional infor-
mation. To narrow the search in HAECs, we hypothesized that the operational TFs would be highly
expressed and that their genetic loci would contain super-enhancers (SEs), or unusually dense clus-
ters of highly decorated enhancers (Hnisz et al., 2013). Characterization of enhancer marks across
cell-types has found SEs to be frequently located at loci encoding lineage-defining
TFs (Whyte et al., 2013; Dowen et al., 2014). We queried rank-ordered expression data for TF fam-
ily members and found that multiple members of each group were highly expressed (Figure 1d). For
example, SOX members SOX18, SOX4, and SOX17 were among the top 4% most expressed TFs in
HAECs. AP1 family members JUND, JUN, and JUNB were also in the top 4%. RNA-seq from other
HAEC donors and replicate samples confirmed these findings (Figure 1—figure supplement 1).
Next, we defined SEs using H3K27ac ChIP-seq data and found that, among others, the genetic loci
for ERG (an ETS member) as well as AP1 members JUN, JUND, and JUNB harbored SEs (Figure 1e,
f, Figure 1—figure supplement 2). Taken together, these data suggest that while multiple TFs from
each family probably bind HAEC enhancers, that JUN, JUNB, JUND, and ERG likely serve prominent
roles.
Roughly half of HAEC enhancers are endothelial-specific
To investigate which enhancer-like elements discovered in HAECs were specific to ECs, we analyzed
public H3K27ac ChIP-seq datasets from ENCODE (ENCODE Project Consortium, 2012) and Road-
map Epigenomics consortia (Kundaje et al., 2015). Considering ECs are present in nearly all tissues,
we focused on data collected in single cell types with the exception of ‘aorta’, ‘right ventricle’, ‘left
ventricle’, and ‘right atrium’ that were included to observe their relationship to aortic endothelium.
A total of 61 datasets were analyzed (Supplementary file 1). Human umbilical vein ECs, or HUVECs,
were the only other EC type in the analysis. H3K27ac ChIP-seq tags were counted and normalized in
each experiment at the 16,929 HAEC-defined enhancer loci. Hierarchical clustering resolved three
distinct clusters of enhancers: an endothelial-specific set (n = 7405), a set common across cell types
(1575), and a mixed set where only some cell types exhibited H3K27ac modification (7949) (Fig-
ure 1—figure supplement 3). Motif analysis of these three sets revealed differential frequencies of
AP1, ETS, SOX, and GATA motifs (Figure 1—figure supplement 3). AP1 and ETS motifs were least
frequently observed in the common enhancer set, while the ETS, GATA, and SOX motifs were most
frequently observed in the endothelial-specific enhancer set. These data are consistent with the
model that different combinations of transcription factors maintain cell-specific gene expression
programs.
Aortic endothelial enhancers overlap genome-wide association SNPs
for CAD and hypertension
To investigate whether EC enhancers have utility to prioritize non-coding functional variants for the
cardiovascular diseases CAD and hypertension, we overlapped physical coordinates of the 16,929
enhancers from Figure 1a with GWAS associated variants. SNPs meeting genome-wide significance
Figure 1 continued
DOI: 10.7554/eLife.22536.002
The following figure supplements are available for figure 1:
Figure supplement 1. Analysis of motifs and expression of associated transcription factors.
DOI: 10.7554/eLife.22536.003
Figure supplement 2. Genetic loci for JUN, JUNB, and JUND.
DOI: 10.7554/eLife.22536.004
Figure supplement 3. Hierarchical clustering of enhancers.
DOI: 10.7554/eLife.22536.005
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for CAD or hypertension, which is a major risk factor for atherosclerosis and CAD, were downloaded
from the NHGRI-EBI GWAS Catalog (Welter et al., 2014). To account for linkage disequilibrium (LD,
the correlation of alleles) between closely spaced SNPs on the same chromosome, we used 1000
Genomes data (Auton et al., 2015) to retrieve SNPs in LD with the reported GWAS SNPs when r2
was greater than 0.8 based on European haplotype structure. We identified 16 SNPs that were
within HAEC enhancers (Table 1) and represent 22 lead SNPs from GWAS studies. Fifty percent of
overlapping SNPs were within EC-specific enhancers (as opposed to those common or mixed across
cell types), whereas only 43% of enhancers in HAECs are EC-specific (Figure 1—figure supplement
3). These data provide a focused list of potential functional non-coding variants that affect predispo-
sition to CAD and hypertension through EC gene regulation. Further studies will be required to
establish the regulatory consequence and predisposing mechanisms of these variants. Nonetheless,
our evidence that perturbed endothelial expression contributes to vascular disease underscores the
importance of elucidating endothelial gene regulatory programs in homeostasis and inflammatory
environments.
TF expression dynamics across 97 HAEC donors nominates three major
modules of TFs as coordinating gene expression
We next questioned how AP1, ETS, SOX, and GATA TFs were expressed in artery ECs across the
human population. We postulated that the most prominent actors would be highly expressed with
modest variation between people. By leveraging global transcript levels collected across 97 geneti-
cally distinct HAECs from healthy human donors (Romanoski et al., 2010), we found that JUN and
JUND (AP1) and ERG (ETS) exhibited the greatest median expression values with relatively little vari-
ability across the EC donor population (Figure 2a).
To gain insight into the behavior of the TF members with respect to each other, we measured co-
variation in TF gene expression profiles across the human population. Co-variation, or co-expression,
of TFs could result from one TF (in)directly regulating another, both (in)directly regulating each
other, or from each being regulated by a common third mechanism. By clustering pair-wide correla-
tion coefficients across all TFs of interest, we identified three main groups with similar co-expressed
profiles: group 1 (in orange) with members FOSL1 and ETS1; group 2 (in green) with GATA2 and
GATA6; and group 3 (in yellow) with the remaining factors (Figure 2b, detailed examples in
Figure 2c-f). The degree of correlation between TFs is indicated by red intensity (anti-correlation
with blue; no correlation with white). Notably, TF expression of groups 1 and 2 were mostly anti-cor-
related with group three members. A very similar grouping of these TFs was observed when their
relationship to all expressed genes was used as the clustering parameter (Figure 2—figure supple-
ment 1). The result that FOSL1 and ETS1 are anti-correlated in expression with the remaining family
members, and to HAEC transcripts overall, suggests that they promote opposing gene expression
profiles in HAECs.
Nominated factors, including ERG and JUN, bind HAEC enhancers at
closely spaced motifs
To test whether the nominated TFs indeed bound HAEC enhancers, we performed the first chroma-
tin immunoprecipitation sequencing (ChIP-seq) experiments for JUNB, JUN, and ERG in HAECs and
analyzed GATA2(ENCODE Project Consortium, 2012) and ETS1 (Zhang et al., 2013) binding data
from human umbilical vein endothelial cells (HUVECs). The JUND cistrome would also be informative
in these studies; however, we proceeded with JUN and JUNB because the heterodimeric binding of
AP1 factors makes it likely that JUN and JUNB profiles encompass a major portion of the overall
AP1 landscape. JUN, JUNB, ETS1, and GATA2 were all confirmed to bind active HAEC enhancers in
the open chromatin region (Figure 2—figure supplement 2). As determined by clustering of bind-
ing profiles, JUNB and JUN were similar and ERG and ETS1 were similar, supporting the role of
canonical DNA motifs on factor recruitment. Next, we asked if there was enrichment of other motifs
proximal to the bound motifs as was observed previously for TF pairs known to collaboratively acti-
vate cell-specific enhancers (Heinz et al., 2010; Gosselin et al., 2014). For this analysis, loci for the
bound factor (e.g. ERG) were centered on the respective motif (e.g. ETS motif) and sites lacking the
motif were omitted. Then, frequencies of other motifs were calculated as a function of distance to
the reference motif. We found that AP1 motifs were most frequently oriented within 50 base pairs
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Table 1. Overlap of HAEC enhancers with GWAS loci reported for coronary artery disease (CAD) or hypertension (HT). Associated
SNPs were downloaded from the NHGRI-EBI Catalog of published genome-wide association studies. SNPs in linkage disequilibrium
(LD) to GWAS association traits were calculated when r2 >0.8 according to the European reference population of the 1000 Genomes
Project. HAEC enhancers defined in Figure 1a were overlapped by physical position (hg19 genome build). The GWAS SNP, p-value,
GWAS trait, gene reported, PMID, overlapping HAEC enhancer coordinates and enhancer type are shown.
GWAS SNP HAEC enhancer
SNP in
enhancer
LD to lead SNP from
study
p-Value of
lead Trait
Reported gene of
lead PubMed ID
Position
(chr, start bp, end
bp) Nearest gene Type
rs12091564 Lead 2.0E-07 CAD HFE2 21626137 1, 145395579,
145395699
LOC101928979 common
rs72701850 LD, rs12091564,
r2 = 0.95346
2.0E-07 CAD HFE2 21626137 1, 145396840,
145397006
LOC101928979 common
rs72701850 LD, rs10218795,
r2 = 0.95346
2.0E-07 CAD HFE2 21626137 1, 145396840,
145397006
LOC101928979 common
rs56348932 LD, rs17114036,
r2 = 0.916823
4.0E-19 CAD PLPP3 21378990,
24262325
1, 56988477,
56988661
PLPP3 EC-
specific
rs56348932 LD, rs9970807,
r2 = 0.942868
2.0E-09 CAD PLPP3 26343387 1, 56988477,
56988661
PLPP3 EC-
specific
rs56348932 LD, rs17114046,
r2 = 0.942868
3.0E-07 CAD PLPP3 21846871,
21378988
1, 56988477,
56988661
PLPP3 EC-
specific
rs10047079 LD, rs2229238,
r2 = 0.866848
7.0E-07 CAD ILR6 22319020 1, 154468114,
154468189
SHE EC-
specific
rs55916033 LD, rs10496288, r2 = 1 2.0E-09 HT intergenic 21626137 2, 83278987,
83279062
LOC1720 EC-
specific
rs55916033 LD, rs10496289, r2 = 1 2.0E-09 HT intergenic 21626137 2, 83278987,
83279062
LOC1720 EC-
specific
rs72836880 LD, rs10496288, r2 = 1 2.0E-09 HT intergenic 21626137 2, 83308909,
83309314
LOC1720 EC-
specific
rs72836880 LD, rs10496289, r2 = 1 2.0E-09 HT intergenic 21626137 2, 83308909,
83309314
LOC1720 EC-
specific
rs112798061 LD, rs10496289, r2 = 1 2.0E-09 HT intergenic 21626137 2, 83308909,
83309314
LOC1720 EC-
specific
rs3748861 LD, rs13420028,
r2 = 0.916266
1.0E-10 HT GPR39 21626137 2, 133196310,
133196505
GPR39 mix
rs3748861 LD, rs10188442,
r2 = 0.916266
1.0E-10 HT GPR39 21626137 2, 133196310,
133196505
GPR39 mix
rs144505847 LD, rs6725887, r2 = 1 1.0E-09 CAD WDR12 21378990,
24262325
2, 203672243,
203672412
ICA1L EC-
specific
rs144505847 LD, rs7582720, r2 = 1 3.0E-08 CAD WDR12 24262325 2, 203672243,
203672412
ICA1L EC-
specific
rs56155140 LD, rs17087335,
r2 = 0.979112
5.0E-08 CAD NOA1, REST 26343387 4, 57824385,
57824541
NOA1 mix
rs5869162 LD, rs6452524,
r2 = 0.924698
2.0E-07 HT XRCC4 21626137 5, 82393827,
82393921
XRCC4 EC-
specific
rs5869162 LD, rs6887846,
r2 = 0.924698
2.0E-07 HT XRCC4 21626137 5, 82393827,
82393921
XRCC4 EC-
specific
rs6475604 LD, rs7865618,
r2 = 0.940597
2.0E-27 CAD MTAP 21606135 9, 22052677,
22052823
CDKN2B EC-
specific
rs17293632 LD, rs72743461, r2 = 1 1.0E-07 CAD SMAD3 26343387 15, 67442510,
67442670
SMAD3 common
rs17293632 LD, rs56062135,
r2 = 0.988489
5.0E-09 CAD SMAD3 26343387 15, 67442510,
67442670
SMAD3 common
rs17227883 LD, rs17228212,
r2 = 0.981438
2.0E-07 CAD SMAD3 17634449 15, 67442769,
67443128
SMAD3 common
Table 1 continued on next page
Hogan et al. eLife 2017;6:e22536. DOI: 10.7554/eLife.22536 6 of 28
Research article Genes and Chromosomes Human Biology and Medicine
to ERG-bound ETS motifs and that AP1 motif presence decayed with distance from the ETS motif
(Figure 3a). Reciprocally, ETS motifs were most frequently observed proximal (within 50 base pairs)
to JUN/JUNB co-bound AP1 motifs (Figure 3b). Both AP1 and ETS motifs were frequently observed
near GATA2-bound GATA motifs; however, neither GATA nor SOX motifs were prominent in the
vicinity of ETS or AP1-bound motifs (Figure 3c). These data support that AP1 and ETS factors collab-
orate to determine the active chromatin landscape in HAECs with GATA and SOX serving less active
roles genome-wide. This observation is consistent with GATA and SOX motifs only having enrich-
ment in EC-specific enhancers (Figure 1—figure supplement 3).
Allele-specific binding to chromosomes lacking motif mutations
supports collaborative binding between AP1 and ETS factors
One approach to study collaborative binding between TFs is to knock-down/out a TF of interest and
observe a shift in binding or activity at the regulatory element. To avoid complications in interpret-
ability caused by potential redundancy of TF members, we took an alternative approach. As applied
in inbred mouse strains previously (Heinz et al., 2013; Gosselin et al., 2014), we utilized naturally
occurring genetic variation as a genome-wide source of motif mutations. The hypothesis is if the
motif for a collaborative transcription factor is mutated then it should affect binding of the collabo-
rating transcription factor whose motif remains in tact. To test this, whole-genome sequencing
(WGS) of one HAEC donor was performed at an average of 40X coverage and the identified SNPs
were phased with the appropriate 1000 Genomes (Auton et al., 2015) reference population (see
Materials and methods). To quantify JUN binding to distinct homologous chromosomes at heterozy-
gous loci, JUN ChIP-seq reads were iteratively mapped to human genome builds containing the
appropriate allele. Sequence tags with discrepant mappings were omitted to avoid bias. For all loci
with a JUN peak containing at least one heterozygous SNP, ChIP-seq tags were counted that could
be uniquely assigned to one homologous chromosome. These data were then analyzed with respect
to loci where only one SNP allele mutated either the AP1 or ETS motif.
Results showed that JUN binding was significantly affected by mutations in the AP1 motif
(p = 5.0e-10) such that binding was predominant on the chromosome lacking AP1 motif mutations
and diminished on chromosomes containing the mutation (Figure 3—figure supplement 1). Inter-
estingly, JUN binding was also significantly affected by mutations in the ETS motif that occurred
within 100 base pairs of the JUN peak center (Figure 3d p-value = 2.6e-3). We would expect to
observe the reciprocal relationship, in which AP1 motif mutations alter ERG binding, but the ERG
ChIP-seq experiment in the sequenced HAEC donor yielded less than ten thousand peaks and more
information is necessary for this analysis. Taken together, these data support a collaborative relation-
ship between AP1 and ETS factors at endothelial enhancers.
JUN and ERG co-occupy multiple elements near endothelial-specific
genes
To interrogate the gene targets of JUN and ERG, we began with loci for genes expressed specifi-
cally or predominantly in ECs. All the genes queried, including vascular endothelial cadherin, (CDH5
or VE-cadherin), epidermal growth factor-like protein 7 (EGFL7), von Willebrand Factor (VWF),
Table 1 continued
GWAS SNP HAEC enhancer
SNP in
enhancer
LD to lead SNP from
study
p-Value of
lead Trait
Reported gene of
lead PubMed ID
Position
(chr, start bp, end
bp) Nearest gene Type
rs1563966 LD, rs1231206,
r2 = 0.844151
9.0E-10 CAD intergenic 21378990 17, 2095878,
2096222
LOC101927839 mix
rs1563966 LD, rs216172,
r2 = 0.909315
1.0E-09 CAD SMG6, SRR 21378990,
26343387
17, 2095878,
2096222
LOC101927839 mix
rs7408563 LD, rs7246657,
r2 = 0.900512
7.0E-06 CAD ZNF383 23870195 19, 37808501,
37809067
HKR1 common
DOI: 10.7554/eLife.22536.006
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Figure 2. Coordinate gene expression across 96 genetically distinct HAEC donors identifies three regulatory programs among ETS, AP1, SOX, and
GATA family members. (a) TF gene expression measured by AffyHU133A array is shown across a population of 97 unique HAEC donors. Array probe
set IDs were manually confirmed to cover expressed transcript isoforms of the indicated TFs based on RNA-seq data. Boxplots midlines are medians,
box edges are 1st and 3rd quartiles, and whiskers 95% confidence intervals. (b) A heatmap of clustered pairwise Spearman correlation coefficients
Figure 2 continued on next page
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endothelial nitric oxide synthase (NOS3), and TEK receptor tyrosine kinase (TEK, or TIE2), exhibited
between three and seven ERG/JUN co-bound enhancers across their genetic loci (Figure 3e, Fig-
ure 3—figure supplement 2). By cross-referencing cistromes of ERG and JUN that individually
bound 35,559 and 63,312 genomic loci respectively, we found that 10,919 of the 16,292 (65%) high
confidence enhancers from Figure 1a. were bound by one or both of ERG and JUN (Figure 3f).
Each enhancer was assigned a target gene(s) based on the following criteria. Since nearest genes
are not necessarily the target of enhancer activity, we incorporated expression quantitative trait loci,
or eQTL, that were identified in HAECs (Romanoski et al., 2010). eQTL are SNP-gene pairs that
describe a genetic locus whose alleles are associated with quantitative levels of gene expression val-
ues of the target gene, and thus provide a functional link between DNA sequence and gene regula-
tion. Only 7% of enhancers harbored an eQTL SNP, in which case the associated gene was
considered the target. In the remaining cases, the nearest gene was used. Pathway analysis for the
resulting 4396 target genes for the 4248 ERG and JUN co-bound loci revealed significant enrich-
ment in ‘Cardiovascular system development and function’ (p = 6.1e-37, Figure 3f). Together, these
data support that ERG and JUN are major TFs at EC enhancers, and that their collaborative binding
regulates expression of endothelial-specific genes important in vascular development and function.
ERG knockdown elicits a pro-inflammatory gene expression profile in
HAECs
To test the functional importance of ERG on target gene expression, we knocked-down ERG using
siRNA in HAECs and measured gene expression changes with RNA-seq and RT-qPCR (Figure 4, Fig-
ure 4—figure supplements 1 and 2). ERG RNA was reduced to less than 40% of normal levels in
three independent experiments and resulted in differential expression of up to 1000 transcripts (>4-
fold, FDR < 5%) by RNA-seq. Functional enrichment analysis demonstrated that ERG target genes
are significantly annotated for ‘cell movement’, ‘breast or ovarian cancer’, ‘angiogenesis’, ‘develop-
ment of vasculature’, ‘leukocyte migration’, and other pro-inflammatory functions (p-values from 1e-4
to 1e-17, Figure 4a,b).
Among the most up-regulated genes caused by ERG knockdown were cytokines interleukin one
alpha (IL1a; 16-fold), interleukin one beta (IL1b; 68-fold), leukemia inhibitory factor (LIF; 13-fold),
interleukin 6 (IL6; fourfold), granulocyte colony stimulating factor (CSF3; 41-fold), transforming
growth factor beta 2 (TGFb2; fivefold) and other pro-inflammatory molecules including tissue factor
(F3, 8-fold) (Figure 4b,c, Figure 4—figure supplements 1 and 2). In addition, EC-enriched genes
that had multiple elements bound by ERG, such as CDH5, VWF, PECAM1, EGFL7, NOS3, and TEK
were down-regulated upon ERG knockdown. To ensure that the inflammatory gene profile elicited
by ERG knock-down was not a consequence of transfection itself or off-target effects, the profile
resulting from six individual siERG oligos was measured along with two non-targeting scrambled
siRNA controls and non-transfection controls (Figure 4—figure supplement 2). These data were
reproducible and consistent with ablated ERG expression as the cause of pro-inflammatory expres-
sion profiles. Together, these data suggest that ERG normally functions to maintain EC-specific gene
functions such as development and proliferation while at the same time suppressing inflammatory
gene expression.
Figure 2 continued
across 97 HAEC donors and module designations (colored sidebar) is shown with modules and pairs of interest highlighted by colored outlines. (c–f)
Pairwise Spearman correlations between indicated mRNAs from b where each dot is a genetically distinct HAEC donor. More related data in
Figure 2—figure supplements 1 and 2.
DOI: 10.7554/eLife.22536.007
The following figure supplements are available for figure 2:
Figure supplement 1. The HAEC gene correlation network.
DOI: 10.7554/eLife.22536.008
Figure supplement 2. TF binding at HAEC enhancers.
DOI: 10.7554/eLife.22536.009
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Figure 3. ERG and JUN co-bind EC enhancers and are enriched at EC-specific genes. (a–c) Promoter-distal regions bound by ERG, JUN, and JUNB, or
GATA2 are shown in a, b, and c respectively in a one kilobase window. Each set was centered on the corresponding binding motif, and the frequency
Figure 3 continued on next page
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Oxidized phospholipids and inflammatory cytokines alter HAEC gene
expression through signal-dependent changes to HAEC enhancer
landscapes
To identify regulatory factors that instruct gene expression responses to inflammatory environments
of atherosclerosis, we exposed HAECs to three pro-inflammatory treatments: (i) the oxidized prod-
ucts of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) that are components of
oxidized low-density lipoproteins (oxLDL) (Lee et al., 2012; Romanoski et al., 2011), (ii) tumor
necrosis factor alpha (TNFa) that is a cytokine secreted largely by macrophages, and (iii) interleukin
one beta (IL1b) that is released by many cell types including macrophages. Between 322 and 1174
genes were regulated by these exposures (>2-fold; 5% false discovery rate) (Table 2), and these
genes were enriched in known response pathways (Figure 5—figure supplement 1). For example, 4
hr exposure to 40 mg/ml oxPAPC treatment resulted in up-regulation of genes belonging to the
‘NRF2-mediated oxidative stress response’ (p-value=2.e-13), and the ‘unfolded protein response’ (p-
value=7.0e-7). Genes regulated by 4 hr exposures to TNFa and IL1b were highly enriched in the
same pathways including, ‘TNF receptor signaling’ (p-values from 1.7e-14 to 1.8e-12), ‘granulocyte
adhesion and diapedesis’ (p-values from 2.2e-9 to 7.1e-13), and ‘macrophage, fibroblast and EC roles
in rheumatoid arthritis’ (p-values from 2.1e-12 to 1.7e-13).
To better understand the program that coordinates HAEC response to oxPAPC, TNFa, and IL1b,
we measured enhancer elements genome-wide. We next defined de novo or latent, enhancer-like
elements that are genomic regions that became accessible and gained H3K27ac modification upon
treatment. De novo enhancers result when signal-dependent transcription factors (SDTFs) play a crit-
ical role in the enhancer activation process and, in this study, were used in this study to identify
SDTFs. We identified between 266 and 3199 de novo enhancers across treatments (Figure 5a,
Table 2). To identity the SDTFs, we performed motif enrichment that revealed differential enrich-
ment of TF motifs across treatments (Figure 5b; comprehensive list in Figure 5—source data 1).
For example, the C/EBP, NFkB, and IRF motifs were preferentially enriched in TNFa and IL1b
enhancers, whereas the anti-oxidant response element, or ARE, was enriched in the oxPAPC
enhancer set. In all sets, we found AP1 and ETS motifs were highly enriched (p<1e-6), consistent with
the model that the predominant AP1 and ETS endothelial factors collaborate with newly activated
SDTFs to activate responsive enhancers and direct dynamic gene expression (Figure 5a,b). Enrich-
ment of kB motifs at TNFa and IL1b enhancers is consistent with previous work demonstrating that
NFkB is a master transcription factor of inflammatory gene programs in s as well as other cell types
(Brown et al., 2014). Likewise, oxPAPC-induced enrichment of the ARE motif, to which the TF
nuclear factor, erythroid 2-like 2, or NFE2L2/NRF2 binds, is consistent with reports of single gene
targets that the transcription factor NRF2 regulates the response to oxidative stress (Ma, 2013;
Jyrkka¨nen et al., 2008).
To directly test the hypothesis that NRF2 and NFkB were in fact SDTFs responsible for inflamma-
tory gene responses, we measured the NRF2 cistrome upon oxPAPC treatment and the NFkB cis-
trome (using ChIP-seq with kB-component p65) in TNFa and IL1b 4-hr-treated ECs. NRF2 and p65
binding were associated with increases in H3K27ac on adjacent nucleosomes consistent with a role
Figure 3 continued
of other enriched motifs are shown on the y-axis. GATA2 binding was measured in HUVECs. (d) Allele-specific JUN binding (y-axis) as a function of
allele-specific ETS motif mutations (colored lines). Each vertical line represents a single JUN peak identified via ChIP-seq. For a more complete
explaination see the Figure 3—figure supplement 1 legend and methods section. (e) TF binding for JUN and ERG, the histone modifications
H3K4me2 and H3K27ac and RNA abundance are shown at the genetic loci for VWF and NOS3. Promoters are highlighted in pink and JUN/ERG co-
bound enhancers are highlighted in yellow. (f) The HAEC enhancer set from Figure 1a is annotated for JUN and/or ERG binding. Ingenuity Pathway
Analysis results are shown for the genes nearest the 4248 JUN/ERG co-bound enhancers in the right panel. More related data in Figure 3—figure
supplements 1 and 2.
DOI: 10.7554/eLife.22536.010
The following figure supplements are available for figure 3:
Figure supplement 1. Allele-specific JUN binding at loci with mutated motifs.
DOI: 10.7554/eLife.22536.011
Figure supplement 2. JUN and ERG co-occupy loci near EC-specific genes.
DOI: 10.7554/eLife.22536.012
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Figure 4. ERG knockdown elicits a pro-inflammatory gene profile in HAECs. (a) Genes up-regulated by ERG knockdown (4 fold, 5% FDR) were
enriched in the indicated functional pathways using Ingenuity Pathway Analysis (IPA). Results are from three experiments using cells from different
HAEC donors. ERG levels are shown in c. (b) A network of molecules regulated by ERG knockdown (red = up-regulated; blue = down-regulated) with
membership (lines) to five functional processes. The predicted state of the functional processes is shown by color (activation in red; and inhibited in
Figure 4 continued on next page
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for NRF2 and NFkB as activators of target gene expression (Figure 5—figure supplements 2 and
3). Genome-wide binding of NRF2 with oxPAPC treatment identified 6923 NRF2-bound peaks that
overlapped with 21% of oxPAPC-elicited de novo enhancers. These included gene loci for known
targets including heme oxygenase 1 (HMOX1), thioredoxin reductase 1 (TXNRD1), NAD(P)H quinone
dehydrogenase 1 (NQO1), and glutamate-cysteine ligase modifier subunit (GCLM) (Figure 5—figure
supplement 2). The top four enriched motifs in the NRF2 cistrome were the AP1 motif, an ARE, a
nuclear receptor element (NRE) and the ETS motif. These data suggest that, whereas NRF2 is a sig-
nificant component of the oxPAPC gene response, several additional TFs likely coordinate gene
responses at the chromatin level.
For NFkB, we identified tens of thousands of bound loci after TNFa and IL1b treatment (75,937
and 51,040, respectively). Upon cytokine treatment, 52–63% of the elements that gained p65 were
pre-bound in untreated HAECs by ERG or JUN (Figure 5c), consistent with the working model that
enhancers are selected by lineage-restricted combinations of factors that direct signal-dependent
transcription factor binding profiles (Romanoski et al., 2015). As for de novo enhancers, NFkB had
a major presence and bound to 86% and 55% of those elicited by TNFa and IL1b treatments,
respectively. Motif enrichment of NFkB cistromes in HAECs identified a prominent role of the AP1
motif as well as roles for ETS, IRF, and CEBP factors (Figure 5—figure supplement 3, discussed
below).
In addition, we analyzed allele-specific NFkB binding as a function of motif mutations in the kB
motif itself as well as mutations in the AP1 and ETS motif. Interestingly, we observed that NFkB
binding was diminished at loci where kB, ETS, or AP1 motifs were mutated (Figure 5—figure sup-
plement 4). These data are consistent with collaborative interactions between ETS, AP1, and NFkB
in establishing inflammatory expression profiles in human ECs, and offer a mechanism whereby ECs
may generate cell-specific transcriptional responses to environmental stimuli. Furthermore, these
data demonstrate that allele-specific binding in heterogeneous human cells is a useful means to
reveal collaborative interactions between transcription factors.
Non-random spacing of ETS and kb motifs at co-bound elements
suggest interplay between ERG and NFkB in inflammation
The transcriptional signature resulting from ERG knockdown in aortic ECs (Figure 4) is evidence that
ERG performs an anti-inflammatory role. This has been demonstrated previously, where ERG sup-
pressed IL-8 and NFkB-mediated inflammation in HUVECs (Dryden et al., 2012; Sperone et al.,
Figure 4 continued
blue). Network analysis was performed using IPA and p-values correspond to pathway enrichments. (c) The log2 fold change caused by siERG knock-
down is shown for endothelial-specific genes (blue) and pro-inflammatory genes (pink). Plotted is mean ± SD of fold changes measured in three HAEC
donors. Per donor/gene effects are included in Figure 5—figure supplement 1. Asterisk indicates p-value<0.05 from a paired t-test of siERG to siSCR
values across three donors. More related data in Figure 4—figure supplements 1 and 2.
DOI: 10.7554/eLife.22536.013
The following figure supplements are available for figure 4:
Figure supplement 1. Changes in gene expression with ERG knockdown measured by RNA-seq.
DOI: 10.7554/eLife.22536.014
Figure supplement 2. Changes in gene expression with ERG knockdown measured by RT qPCR.
DOI: 10.7554/eLife.22536.015
Table 2. Molecular trait changes observed upon HAEC exposure to pro-inflammatory stimuli. Differential expression was determined
in DESeq with duplicate RNA-seq experiments.
Stimulus
Regulated genes
(>2 fold, 5%FDR) de novo enhancers increased H3K27ac and accessibility upon stimulation
oxPAPC 4 hr (40 mg/ml) versus control 322 (242 up, 80 down) 839
TNFa 4 hr (2 ng/ml) versus control 840 (611 up, 229 down) 266
IL1b 4 hr (10 ng/ml) versus control 1174 (807 up, 367 down) 3199
DOI: 10.7554/eLife.22536.016
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Figure 5. Inflammatory signals activate enhancer-like elements with distinct motifs and suggest that CEBP and IRF members mediate responsiveness to
TNFa and IL1b. (a) A schematic for de novo enhancer activation by combinations of signal-dependent and collaborative TFs. (b) Enrichments of the
NRF2, NFkB, IRF, C/EBP, AP1, and ETS motifs (y-axis) are shown for de novo enhancer sets activated after 4 hr by either 40 mg/ml oxPAPC (ox), 10 ng/
ml TNFa, or 2 ng/ml IL1b (x-axis). Blue bars show the percent of de novo enhancers containing the motif and red bars indicate the percentage of GC-
matched random genome sequence containing the motif. Motifs were considered within 200 basepair windows of enhancers. (c) ChIP-seq analysis of
Figure 5 continued on next page
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2011; Yuan et al., 2009). One model to explain the relationship between anti-inflammatory effects
of ERG and the pro-inflammatory effects of NFkB at co-bound loci involves the observation that
ERG levels are decreased upon inflammatory stimuli ([Yuan et al., 2009] Figure 6—figure supple-
ment 1a). Depletion of ERG, simultaneous with increased NFkB concentrations, could result in a
functional switch caused by stoichiometric competition between factors. At the pro-inflammatory
target gene ICAM-1, Sperone et. al. demonstrated putative ETS-binding sites within the NFkB motif
at the gene promoter(Sperone et al., 2011). We also observe co-occupancy of ERG and NFkB (p65)
at the ICAM-1 promoter (Figure 6—figure supplement 1b).
To examine the genome-wide relationship between ERG and NFkB occupancy upon inflammatory
signaling, we compared binding profiles. Twenty-nine percent of ERG binding sites in untreated ECs
gained p65 binding upon 4-hr treatment with TNFa, and conversely, 25% of TNFa-elicited p65 bind-
ing occurred at loci pre-bound by ERG (Figure 6—figure supplement 1c). All co-bound loci were
centered on the presumed ETS motif to which ERG binds and the distribution of NFkB motifs within
100 base pairs was calculated. This analysis revealed a distance relationship between ETS and NFkB
motifs that is consistent with ERG and NFkB affecting each other’s binding and activity to promote
pro-inflammatory gene expression (Figure 6—figure supplement 1d). Importantly, however, we do
not observe reduction in ERG binding after TNFa treatment, as would be expected if the factors
were competing for the same element. This is exemplified at the ICAM-1 promoter and in the vari-
ability of TNFa-induced changes to ERG and NFkB binding genome-wide (Figure 6—figure supple-
ment 1e). Together, these data support coordinated regulation of inflammatory pathways by ERG
and NFkB that likely involves multiple mechanisms.
A role for CEBPD and IRF1 in the HAEC response to inflammatory
cytokines
The result that CEBP and IRF motifs were preferentially enriched in TNFa and IL1b-induced
enhancers suggested that TFs in these families direct the EC response to cytokines (Figure 5b). To
identify the likely members, we examined relative expression levels with and without cytokine expo-
sure and found expression of CEBP and IRF factors to be relatively low in untreated HAECs. Upon
TNFa and IL1b exposure, however, CEBPD and IRF1 transcription were highly induced (Figure 5d).
In order for CEBPD and IRF1 to participate in enhancer activation, we reasoned they would need to
be expressed prior to 4 hr when de novo motifs were measured. Indeed, a time-course experiment
confirmed that both CEBPD and IRF1 RNAs were induced after cytokine treatment with a peak
expression at 2 hr (Figure 5e).
Figure 5 continued
p65-binding sites shows regions of the genome that are co-bound by p65 and JUN, p65 and ERG, all three, or solely p65 post treatment by 10 ng/ml
IL1b and 2 ng/ml TNFa treatment. (d) Gene expression, measured by RNA-seq is shown by heatmap for TFs of the C/EBP and IRF families. Expression
values are shown from two HAEC donors and replicate samples. (e) RT-qPCR analysis shows CEBPB, CEBPD, and IRF1 expression from 0 to 24 hr post
treatment by 10 ng/ml IL1b and 2 ng/ml TNFa treatment. Plotted are mean ± S.D., experiment performed with biological triplicates. * represents
p<0.05 by t-test. More related data in Figure 5—figure supplements 1–4.
DOI: 10.7554/eLife.22536.017
The following source data and figure supplements are available for figure 5:
Source data 1. Motif enrichments in 100 bp sequences defined by promoter-distal (3 kb) loci gaining ATAC-seq and H3K27ac upon 4 hr oxPAPC,
TNFa, and IL1b treatments.
DOI: 10.7554/eLife.22536.018
Figure supplement 1. The transcriptional response to oxPAPC, TNFa, and IL1b.
DOI: 10.7554/eLife.22536.019
Figure supplement 2. Signal-responsive transcription factor NRF2 binds endothelial enhancers.
DOI: 10.7554/eLife.22536.020
Figure supplement 3. Signal-responsive transcription factor NFkB binds endothelial enhancers.
DOI: 10.7554/eLife.22536.021
Figure supplement 4. Binding of p65 at mutated motifs at each allele p65 (NFkB) binding was measured by ChIP-seq in a HAEC donor with whole-
genome sequencing information.
DOI: 10.7554/eLife.22536.022
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Figure 6. CEBPD and IRF1 knockdown effect on gene expression response to TNFa. (a) Binding of p65, CEBPD, and IRF1 was measured by ChIP-seq
and is shown at de novo enhancers elicited by IL1b (e) and TNFa (f). Factor binding was measured by CHIP-seq upon 4-hr cytokine treatment, with
binding of CEBPD measured after IL1b only. (b) Factor binding, H3K27ac, and mRNA expression is shown at the CEBPD locus in control-treated and
TNFa-treated HAECs. CEBPD mRNA is shown in the bottom three tracks as a function of control knockdown (siSCR), CEBPD knockdown, and ERG
Figure 6 continued on next page
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Next, we measured binding of IRF1 and CEBPD genome-wide after cytokine treatment
(Figure 6a). For IRF1, we observed binding to the minority (<10%) of de novo enhancers, and when
we did observe binding it was most frequently co-bound with either NFkB or CEBPD. On the other
hand, CEBPD bound to a significant proportion of IL1b and TNFa de novo enhancers (34% and 28%,
respectively), mostly in conjunction with NFkB. Of all de novo enhancers, 24–26% were co-bound by
NFkB and CEBPD within 200 basepairs of each other, strongly suggesting that these factors
together regulate target gene expression.
Notably, ERG and NFkB bind to elements at the CEBPD locus and ERG knockdown induces
CEBPD expression (Figure 6b). These data are consistent with a model whereby cytokine treatment
causes down-regulation of ERG as well as nuclear entry and binding of NFkB. These two events
induce CEBPD expression and enable CEBPD and NFkB to co-bind enhancers of target genes.
Lastly, we tested whether reducing CEBPD and IRF1 levels with siRNA would dampen the endo-
thelial response to cytokines. As hypothesized, CEBPD knockdown to less than 20% control RNA lev-
els resulted in dampened fold-change ratios for genes up-regulated by TNFa (250 genes up-
regulated in siCEBPD compared to 497 in scrambled control; Figure 6c, bottom triangle). Genes in
this set contained inflammatory molecules including vascular cell adhesion molecule 1 (VCAM1),
E-selectin (SELE), IL1A, IL1b, and F3 (Figure 6d). However, lesser induction was partly due to an
increase in these molecules in the untreated state (Figure 6—source data 1) suggesting that CEBPD
may play an anti-inflammatory role at baseline. In the IRF1 knockdown, the most prominent locus
affected was a stretch of related antiviral proteins called ‘interferon-induced proteins with tetratrico-
peptide repeats’ (IFITs) on chromosome 10q23 (Figure 6e). We found that IRF1 bound six elements
along this locus including at the promoters of IFIT2, IFIT3, IFIT1, and IFIT5. IRF1 knockdown reduced
the basal levels of RNA from these genes and likewise prevented induction upon TNFa treatment,
suggesting that IRF1 plays a critical role in their regulation. Together, these data provide evidence
that CEBPD and IRF1 tune cytokine-induced regulatory function that is dominated by NFkB. How-
ever, further studies will be required to understand the precise role that IRF1 and CEBPD have in
aortic EC gene regulation.
Discussion
In this study, we provide the first detailed characterization of human aortic endothelial enhancers at
baseline and under inflammatory conditions using a combination of genome-wide approaches. We
observe that ETS, AP1, GATA, and SOX motifs are enriched in active EC enhancers, and we provide
evidence that ETS and AP1 factors bind the majority of active enhancers in aortic ECs. Allele-specific
binding paired with allele-specific motif mutations provided further evidence of collaborative bind-
ing between AP1, ETS, and kB factors. Our work demonstrates that knockdown of the ETS factor
ERG results in a pro-inflammatory expression profile and corresponding down-regulation of EC-
enriched genes. Further, we identify several hundred de novo enhancers formed in response to pro-
inflammatory molecules abundant in the atherosclerotic plaque: namely, oxidized phospholipids and
the cytokines TNFa and IL1b. Motif enrichments paired with expression changes prioritized NFkB,
CEBPD, and IRF1 as the responsible coordinators of cytokine response and NRF2 as a coordinator
of response to oxidized phospholipids. Our work provides valuable context to the role of these tran-
scription factors within the regulatory networks controlling the endothelium in physiologic and dis-
ease states.
Figure 6 continued
knockdown. (c) A global view of mRNA responses to TNFa as a function of CEBPD knockdown (y-axis) compared to control (x-axis); mean ± S.D. (d) The
response to TNFa is shown for molecules of interest in control (siSCR) and CEBPD knockdown HAECs. (e) The IFIT locus, highlighting elements co-
bound by IRF1 and NFkB (p65). More related data in Figure 6—figure supplement 1.
DOI: 10.7554/eLife.22536.023
The following source data and figure supplement are available for figure 6:
Source data 1. Transcripts up-regulated by more than twofold by CEBPD knockdown in untreated HAECs compared to scrambled control.
DOI: 10.7554/eLife.22536.024
Figure supplement 1. ERG and p65 co-bind loci with a distinctive ETS/NFkB motif.
DOI: 10.7554/eLife.22536.025
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Our approach was to learn the regulatory lexicon of ECs beginning with H3K4me2-positive,
H3K27ac-positive, accessible DNA sequence. In doing so we identified a set of TF families, each of
which possesses many highly expressed members and inter-correlated expression patterns across
aortic ECs from 97 people (Figure 2). Of note, whereas SOX members (SOX4/17/18) were among
the most abundant of all TFs in aortic ECs, the SOX motif was not as highly enriched at EC
enhancers as AP1 and ETS motifs (Figures 1b, c and 3a). An explanation for this could be that SOX
factors are critical for the selection of key endothelial enhancers in lineage development, and that
only some of these enhancers remain open and available for other factor binding. This would explain
the moderate enrichment of SOX motifs and is consistent with the role of SOX17 and SOX 18 in
angiogenesis and vascular integrity (reviewed by [De Val and Black, 2009]). However, we acknowl-
edge that this theory does not explain why ECs persistently express such high levels of SOX mRNAs.
Another explanation, consistent with the selective enrichment of SOX and GATA motifs only in EC-
specific enhancers (Figure 1—figure supplement 3) is that these factors play localized but impor-
tant roles on target genes.
The finding that the ETS and AP1 factors ERG and JUN together bind the majority of EC
enhancers, and co-bind key EC loci, supports a prominent and collaborative role for these factors in
selecting endothelial specific enhancers. Our analysis of motif mutations further exemplifies a co-
dependence of these factors in enhancer binding. While we focus on ERG and JUN in particular,
other combinatorial interactions between other ETS and AP1 members almost certainly play promi-
nent roles in endothelial regulation. Still, our findings are consistent with previous reports that ERG
is among several ETS transcription factors critical for endothelial lineage development (De Val and
Black, 2009; Nikolova-Krstevski et al., 2009; Shah et al., 2016) and regulation of candidate endo-
thelial genes such as CDH5, VWF, and eNOS (Yuan et al., 2009; Birdsey et al., 2008;
Laumonnier et al., 2000). Knockdown of ERG in aortic ECs revealed two notable effects, namely a
reduction in EC-specific gene expression, and production of a pro-inflammatory transcriptional pro-
file. The first of these effects is in keeping with our results demonstrating that ERG and AP1 co-bind
promoters and enhancer elements at key endothelial gene loci. This supports our model whereby
ERG binds collaboratively with AP1 factors to drive a basal lineage-defining transcriptional network
in ECs.
Functional interactions between ETS and AP1 family members have been previously
described (Bassuk and Leiden, 1995), and cooperative binding of ETS factors and FOS/JUN occurs
at adjacent ETS and AP1 motifs with variable spatial orientation (Kim et al., 2006). In the current
study, we also observe a spike in AP1 motifs near ETS motifs consistent with precise spatial orienta-
tion at some loci (Figure 3a,b), although this motif relationship does not describe the majority of
genome-wide ERG and JUN co-binding we observe.
The transcriptional signature resulting from ERG knockdown in aortic EC also further supports the
anti-inflammatory role for ERG, which has been demonstrated in HUVECs (Dryden et al., 2012;
Sperone et al., 2011; Yuan et al., 2009). Our observation of regularly spaced ETS and kB motifs at
co-bound loci suggests interplay between these two TF families. However, we do not observe coor-
dinated change in genome-wide binding for ERG and NFkB upon TNFa treatment, indicating that
these factors act in ways other than competitors for binding (Figure 6—figure supplement 1). In
addition, we demonstrate ERG to regulate expression of numerous transcription factors
(Supplementary file 2) that likely regulate secondary transcriptional targets. Recent work in murine
EC has also demonstrated a role for ERG in promoting vascular integrity through promotion of
canonical Wnt-signaling, via stabilization of b-catenin (Birdsey et al., 2015). This highlights the
potential that ERG influences endothelial function through multiple mechanisms. Our present work
underscores a role for ERG in promoting endothelial homeostasis and in regulating the inflammatory
response. It also broadens our perspective of its regulatory function and cooperation with other fac-
tors genome-wide.
Our finding that the CEBP motif was enriched at TNFa and IL1b-induced enhancers and that
CEBPD transcript levels were highly induced after treatment supported its role in binding inflamma-
tory enhancers (Figure 5). CEBPD knockdown in aortic ECs in the absence of TNFa or IL1b caused
modest up-regulation of pro-inflammatory molecules including ICAM1, SELE, IL1a, and IL1b (Fig-
ure 6, Figure 6—source data 1), suggesting that CEBPD maintains an anti-inflammatory expression
profile in resting ECs. This is consistent with an anti-inflammatory role of CEBPD in pancreatic beta
cells in the setting of cytokine stimulation (Moore et al., 2012). However, upon TNFa and IL1b
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stimulation in aortic ECs, CEBPD knockdown also dampened this inflammatory response as com-
pared to untreated ECs suggesting that in fact CEBPD is required for full responsiveness to cyto-
kines (Figure 6). This is consistent with previous reports showing CEBPD to be up-regulated in many
inflammatory settings including atherosclerosis (Takata et al., 2002; Ko et al., 2015). Going for-
ward, a key part of elucidating the role of SDTF such as CEBPD will be to quantify their loss-of-func-
tion effect on de novo enhancers that arise upon inflammatory stimuli. Given our hypothesis of
hierarchical transcription factor binding, we would expect to observe loss of some of these
enhancers following SDTF inhibition. Complicating this approach, however, is that inflammatory
stimuli often induce expression of SDTFs. For example, NFkB binds the promoter of CEBPD
(Figure 6b). Therefore, targeted mutagenesis strategies, such as the CRISPR-Cas9 system, will be
required to fully eliminate SDTF function and interpret the data. Overall, these findings motivate fur-
ther experiments to fully understand the regulatory function of CEBPD.
Cell type and context-specific enhancer mapping is a critical approach toward fully understanding
regulatory disease mechanisms, as many disease loci reside in non-coding DNA sequence. Nonethe-
less, enhancers are a challenge to measure in pure human cell types relevant to many diseases. We
provide a list of candidate SNPs with potential EC-specific non-coding regulatory function (Table 1).
This is an important step toward fully understanding the etiology and molecular pathogenesis of
CAD in humans. In conclusion, our study of dynamic endothelial enhancer elements is an advance-
ment toward a systems-levels understanding of vascular inflammatory diseases.
Materials and methods
Cell culture
HAEC were isolated as described (Navab et al., 1988) from aortic trimmings of donor hearts at the
University of California, Los Angeles (UCLA). All HAECs were de-identified and exempt from consid-
eration as human subjects research by institutional regulatory boards at UC San Diego and The Uni-
versity of Arizona. Cells were grown in culture in M-199 (ThermoFisher Scientific, Waltham, MA, MT-
10–060-CV) supplemented with 1.2% sodium pyruvate (ThermoFisher Scientific, Catalog#
11360070), 1% 100X Pen Strep Glutamine (ThermoFisher Scientific Cat# 10378016), 20% fetal bovine
serum (FBS, GE Healthcare, Hyclone, Pittsburgh, PA), 1.6% Endothelial Cell Growth Serum (Corning,
Corning, NY, Product #356006), 1.6% heparin, and 10 mL/50 mL Amphotericin B (ThermoFisher Sci-
entific #15290018). Cells were grown to 90% confluence in either 10-cm or 15-cm plates, and used
primarily at passages 6 to 10. Cells were then treated with M-199 containing 1% FBS (control) or
additionally containing either 40 mg/mL Ox-PAPC, 2 ng/mL human recombinant TNFa, or 10 ng/mL
human recombinant IL1b (cytokines from R&D Systems, Minneapolis, MN).
Small-interfering RNAs and qPCR Primers
Knockdown of ERG, CEBPD, and IRF1 were performed using 1 nM siRNA oligonucleotides in Opti-
MEM (ThermoFisher Scientific) with Lipofectamine 2000 (ThermoFisher Scientific). Transfections were
performed in serum-free media for 4 hr, then cells were grown in full growth media for 48 hr. All
siRNAs and qPCR primers used in this study are listed in Supplementary file 3.
RNA-seq
HAECs were resuspended in RNA Lysis Buffer and RNA was extracted from cells using the Quick-
RNA Micro Prep kit from ZymoResearch (Irvine, CA, #R1051), including optional DNase I treatment.
mRNA was selected through poly-A isolation using Oligo d(T)25 beads (New England
BioLabs, Ipswich, MA, #S1419S). Selected RNA was fragmented, followed by single strand cDNA
synthesis using a SuperScript III First-Strand Synthesis System (ThermoFisher Scientific # 18080051),
followed by second strand synthesis using DNA Polymerase I (Qiagen/Enzymatics, Beverly, MA,
#P7050L). dsDNA ends were repaired with T4 DNA Polymerase (Enzymatics #P7080L). Barcode
adapters (BIOO Scientific NEXTflex, Austin, TX, #514104) were ligated onto the ends of sequences
using T4 DNA Ligase (Enzymatics #L-6030-HC-L) and samples were treated with Uracil DNA Glycosy-
lase (UDG) (Enzymatics #G5010L). Libraries were then amplified by PCR (Phusion Hot Start
II, ThermoFisher Scientific, #F549L) and purified (Zymo #D5205) for high-throughput sequencing.
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Chromatin immunoprecipitation sequencing (ChIP-seq)
ChIP-seq was performed as previously described (Gosselin et al., 2014). Briefly, HAECs were fixed
at room temperature with 1% paraformaldehyde in PBS for 10 min, and then quenched with glycine.
ChIPs for p65, JUN, and JUNB were performed from chromatin cross-linked by 2 nM Disuccinimidyl
Glutarate Crosslinker (DSG) (ProteoChem, Hurricane, UT, #c1104) in PBS for 30 min followed by 1%
paraformaldehyde in PBS for 15 min, and then quenched with glycine. Between 2 and 10 million cells
were used for each ChIP-seq. Cell lysates were sonicated using a BioRuptor Standard or BioRuptor
Pico (Diagenode, Belgium), and then immunoprecipitated using antibodies bound to a 2:1 mixture
of Protein A Dynabeads (Invitrogen #10002D) and Protein G Dynabeads (Invitrogen #10004D). Anti-
bodies used included H3K4me2 (EMD Millipore, Billerica, MA, #07–030), H3K27ac (Active
Motif, Carlsbad, CA , #39135), CEBPD (Santa Cruz Biotechnology, Dallas, TX, #sc-636X), IRF1 (Santa
Cruz #sc-497x), p65 (Santa Cruz #sc-372X), NRF2 (Santa Cruz #sc-1694X), JUN (Santa Cruz #sc-
13032X), ERG (Santa Cruz #sc-354X), and JUNB (Santa Cruz #sc-73). Following immunopreciptation,
crosslinking was reversed and libraries were prepared using the same method described for RNA-
seq beginning with dsDNA end repair and excluding UDG. For each sample condition, an input
library was also created using an aliquot of sonicated cell lysate that had not undergone immunopre-
cipitation. These samples were sequenced as below and used to normalize ChIP-seq results.
Transposase-accessible chromatin using sequencing (ATAC-seq)
ATAC-seq was performed on 50,000 HAEC nuclei according to the original published
protocol (Buenrostro et al., 2013) with the exception of size selection (125–175 base pairs on TBE
gel) prior to sequencing to enrich for enhancer elements.
Sequencing data samples, mapping, and normalization
Libraries were sequenced on an Illumina HiSeq 4000 according to manufacturer’s specifications at
the University California San Diego and at the University of Chicago. Public data was downloaded
from public repositories and processed exactly as new data in this study (see below). Reads from
ChIP-seq and ATAC-seq were mapped to the hg19 build of the human genome with
Bowtie2 (Langmead and Salzberg, 2012) and RNA-seq reads were mapped with
STAR (Dobin et al., 2013). For ATAC-seq, reads mapping to mitochondrial DNA were discarded.
Mapped reads were organized into HOMER’s preferred data structure called Tag Directories using
the ‘makeTagDirectory’ command.
ATAC-seq and RNA-seq experiments that measured accessibility and expression in different
treatment stimuli (control, oxPAPC, IL1b, and TNFa) were all conducted at least twice. ERG knock-
down was performed in three different HAEC donors. CEBPD and IRF knockdowns were performed
in one HAEC donor. The Benjamini-Hochberg false discovery rate (FDR) method was used to correct
for all multiple testing in this study. No explicit power analysis was used to compute sample size.
Instead, genome-wide features such as enhancer elements served as the replicates for motif analysis
and duplicate ChIP-seq experiments confirmed that binding peaks were consistent. With the excep-
tion of CEBPD and JUNB that were performed one time, all ChIP-seq experiments were performed
in biological duplicate, meaning separate cell expansion and collection.
RNA-seq analysis
For quantification, RNA-seq was normalized using Reads Per Kilobase of transcript per Million
mapped reads (RPKM) procedure in HOMER (Heinz et al., 2010). RNA sequencing tags were only
considered when they mapped to the same DNA strand as indicated by RefSeq annotation. Further,
only tags in exons of genes were incorporated as to remove bias created by variable intron sizes.
Together, RNA quantification was achieved using the HOMER command ‘analyzeRepeats rna –
strand + -count exons –rpkm’. In this study, RPKM is synonymous with FPKM (Fragments per kilo-
base mapped). Statistically significant differential expression from RNA-seq experiments was deter-
mined first by unnormalized counts (with analyzeRepeats -noadj) followed by statistical testing in
DESeq (Anders and Huber, 2010) and a restriction to a 5% False Discovery Rate. Pathway enrich-
ment analysis was performed using Ingenuity Pathway Analysis software (Qiagen).
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Peak calling
ChIP-seq and ATAC peaks were identified using un-immunoprecipitated chromain, or ‘input’, as a
negative control. Inputs from the corresponding crosslinking condition were used for each ChIP. No
input was used to call ATAC peaks. Peaks were identified in HOMER with the findPeaks program
according to the data type. Transcription factor peaks were called using the ‘findPeaks -style factor
–size 200’ option and histone peaks called using the ‘findPeaks -style histone’ option. ATAC-seq
peaks were called using findPeaks with ‘-L 8 F 8 -style histone -size 75 -minDist 75 -minTagThreshold
6’ options. Differential peaks between experiments were determined using the ‘getDifferentialPeaks
program with default parameters’ (normalized tag count difference >4 fold and poisson enrichment
p-value<0.0001).
Peak merging was performed in HOMER using the ‘mergePeaks’ program. For enhancers defined
in Figure 1a, the ATAC-seq peak file was merged with peak regions defined in H3K4me2 and
H3K27ac ChIP-seq experiments using the option ‘-d given’ that requires overlap of genomic coordi-
nates between the three peak files. Because the ATAC set was listed first, enhancers were centered
on the center of the accessible region. Distal peaks throughput the study were defined as being at
least three kilobases from the transcriptional start site of a gene (RefSeq hg19 definitions) using
HOMER’s ‘getDistalPeaks.pl’ command.
De novo enhancers and super-enhancers
De novo enhancers were defined as loci that gained ATAC-seq and H3K27ac ChIP-seq in the same
cell simulation. Individual gained peak sets was determined by ‘getDifferentialPeaks’, explained
above, and significant sets were intersected using ‘mergePeaks’ where the ATAC-seq gained peaks
were listed first to maintain centering on accessibility.
Super-enhancers were defined in HOMER from H3K27ac ChIP-seq experiments and correspond-
ing inputs using ‘findPeaks -style super -L 0’. This procedure follows the same logic as the original
definition proposed by the Young laboratory (Whyte et al., 2013). Briefly, the implementation in
HOMER identifies ‘typical’ ChIP-seq peaks, stitches proximal enhancers together, ranks the resulting
enhancers by normalized tag counts over input, and thresholds enhancers above a flex-point
(slope >1) as super-enhancers.
Motif enrichment and distance analysis
Motif enrichment analysis was performed on peak sets using HOMER’s ‘findMotifsGenome.pl’ pro-
gram. As a background control, this program selects a set of sequences from the same genome
build that are matched in size and GC content to the peak set of interest. In Figure 5b, to enable
enrichment comparison for motifs across multiple peak sets, we used HOMER’s ‘findMotifsGenome.
pl –mknown <motifs>’ option iteratively across each de novo enhancer set. For each motif analysis,
the amount of sequence analyzed depended on the data type and is indicated in the text.
Analysis of motif distances in Figure 3a–c was performed in peak regions identified by ChIP-seq
(e.g. ERG-bound in 3a; AP1 bound in 3b; GATA2-bound in 3c). Each peak set was centered on the
highest-scoring TF motif that matched the factor immuno-precipitated, so that 0 bp on the x-axis
was the beginning of the likely bound motif (e.g. the ETS motif for ERG-bound in 3a). Peaks lacking
consensus motifs for the respective factors were excluded from this analysis. Next, the frequency of
the other motifs queried (e.g. AP1, GATA and SOX motifs in 3a) were calculated in HOMER by
‘annotatePeaks.pl –hist –m’ options and the frequency of the additional motifs tested in the vicinity
were plotted to show positional relationships among motifs and surrounding genomic sequence.
Whole-genome sequencing, motif mutation analysis and allele-specific
factor binding
For the HAEC line sequenced for analysis as in Figure 3d, genomic DNA was prepared for paired-
end WGS on Illumina HiSeqX (Illumina, CA) by Novogene (Sacramento, CA) according to manufac-
turer specifications. More than 80 million raw sequencing reads and a raw depth of 41X were
obtained. Data were mapped to the hg19 genome using Burrows-Wheeler Aligner (Li and Durbin,
2009). Single nucleotide variants (SNVs) were identified using GATK (DePristo et al., 2011). SNVs
were then compared to 1000 Genomes reference populations (Auton et al., 2015) and the HAEC
donor clustered with the Mexican American reference (MXL) population by multi-dimensional scaling
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analysis in PLINK (Purcell et al., 2007). SNVs were then phased according to the 1000 Genomes
MXL reference population in BEAGLE (Browning and Browning, 2016; Browning and Browning,
2007).
Allele-specific binding of JUN and NFkB/p65 was quantified using the WASP pipeline (van de
Geijn et al., 2015). To avoid mapping bias caused by alternate alleles, reads that mapped discor-
dantly to reference and alternate alleles at heterozygous SNPs were discarded. Next, sequencing
reads from ChIP experiments were aligned to each haplotype at polymorphic loci and summed
within ChIP-seq peaks for the respective factor.
Allele-specific motif mutations were identified with the same method as reported
previously (Heinz et al., 2013; Gosselin et al., 2014) with slight modifications. In summary, refer-
ence genome sequence (hg19) was extracted at peaks of interest and intersected with SNVs in the
HAEC donor of interest. Phased variant data was pulled for each homologous chromosome and
alleles were inserted in turn to the genome sequence. Motifs were located by alignment to position
weight matrices of ETS, AP1, and kB motifs in HOMER (Heinz et al., 2010). Motif mutations were
defined as instances where motifs were only identified on one of the two homologous
chromosomes.
For visualization, plots as in Figure 3d show the relationship between allele-specific TF binding
and mutations in motifs of interest within the TF peaks containing at least one variant. TF binding
was transformed to the log2 scale and peaks containing 0 reads on one of the two alleles were
scaled to ±7.5 (or else the ratio would be ±Infinity). Boxplots showing the distribution of read ratios
in each category (no mutations, mutation on allele 1, mutation on allele 2) exclude peaks with 0
counts on either chromosomal pair. This is a conservative approach, as many peaks have zero reads
on the mutated chromosome.
Data visualization
Heatmap-syle histograms of sequencing tags (e.g. Figure 1a), were generated using HOMER’s
‘annotatePeaks.pl -ghist’ option and plotted in R using the ‘heatmap.2()’ function of the gplots
library. Cumulative histograms of tag frequencies by position to peak center (e.g. Figure 1c), were
generated using HOMER’s ‘annotatePeaks.pl –hist’ option. Standard heatmaps (e.g. Figure 2b)
were plotted in R using ‘heatmap.2()’ with default clustering parameters (Hierarchical clustering and
Euclidian distance).
Enhancer overlap with GWAS data
Coronary artery disease, hypertension, and related traits were downloaded from the NHGRI-EBI Cat-
alog of published genome-wide association studies (Welter et al., 2014). SNPs in linkage disequilib-
rium (LD) to GWAS association traits were calculated when r2 >0.8 in PLINK (Purcell et al., 2007)
according to the European reference population of the 1000 Genomes Project (Auton et al., 2015).
HAEC enhancers defined in Figure 1a were overlapped by physical position (hg19 genome build).
The studies reporting associations that overlapped EC enhancers are as follows: (Nikpay et al.,
2015; Samani et al., 2007; Coronary Artery Disease (C4D) Genetics Consortium, 2011;
Schunkert et al., 2011; Wild et al., 2011; Slavin et al., 2011; Aouizerat et al., 2011; Mehta, 2011;
Davies et al., 2012; Wojczynski et al., 2013; Dichgans et al., 2014; Kertai et al., 2015).
Public datasets
With the exception of data used to generate Figure 1—figure supplement 3 (see
Supplementary file 1 for list), raw sequencing data was downloaded from Gene Expression Omni-
bus (GEO) as short read archive files and converted to fastq files using ‘fastq-dump’. Fastq files were
mapped to the hg19 genome build in Bowtie2 and processed according to methods outlined for
corresponding data types above. The following publicly available datasets were analyzed: GSE52642
(HAEC GRO-seq), GSE20060 (HAEC microarrays), GSE41166 (ETS-1 HUVEC ChIP-seq), and
GSE31477 (GATA2 HUVEC ChIP-seq).
Data generated in this study is available under GEO accession GSE89970 and WGS via NCBI SRA
Archive, BioProject PRJNA381088.
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Cell lines
The HAECs used in this study were primary isolates of ECs from aortic trimmings collected from
trimmings of donor hearts transplanted through the UCLA heart transplant program as previously
described (Navab et al., 1988). No transformations were performed and they were used at low pas-
sage (p6-p10).
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